Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tazarotene. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARA known ✓ | P10276 | 15/20 | 1.00 |
| ▸ | RARB known ✓ | P10826 | 15/20 | 1.00 |
| ▸ | RARG known ✓ | P13631 | 12/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.77 |
| ▸ | RXRA | P19793 | 2/20 | 0.40 |
| ▸ | CRABP2 | P29373 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tazarotene SCHEMBL5747908 | 1.00 | RARA (1.00) | RARARARBRARGCYP3A4KMT2A | |
| Tazarotene SCHEMBL3134 | 1.00 | RARA (1.00) | RARARARBRARGCYP3A4KMT2A | |
| Tazarotene SCHEMBL29512592 | 1.00 | RARA (1.00) | RARARARBRARGCYP3A4KMT2A | |
| Tazarotene SCHEMBL6101987 | 0.99 | RARA (0.98) | RARARARBRARGCYP3A4KMT2A | |
| Tazarotene SCHEMBL6841186 | 0.95 | RARB (0.90) | RARARARBRARGCYP3A4KMT2A | |
| Tazarotene SCHEMBL995330 | 0.94 | RARB (0.88) | RARARARBRARGCYP3A4KMT2A | |
| SCHEMBL9333830 | 0.92 | RARB (0.86) | RARARARBRARGCYP3A4KMT2A | |
| SCHEMBL8037155 | 0.91 | RARA (0.83) | RARARARBRARGCYP3A4KMT2A | |
| SCHEMBL19560666 | 0.90 | RARA (0.82) | RARARARBRARGCYP3A4KMT2A | |
| Tazarotene SCHEMBL995895 | 0.90 | RARB (0.81) | RARARARBRARGCYP3A4KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 197 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026104588-A1 | UROLITHIN COMBINATION | AMAZENTIS SA (CH) | 2026-05-21 | — | — | WO | claimed |
| US-20260125650-A1 | METHODS AND COMPOSITIONS FOR GENERATING HEPATOCYTES | TRAILHEAD BIOSYSTEMS INC (US) | 2026-05-07 | — | — | US | claimed |
| US-20250304916-A1 | METHODS AND COMPOSITIONS FOR GENERATING VASCULAR LEPTOMENINGEAL CELLS | TRAILHEAD BIOSYSTEMS INC (US) | 2025-10-02 | — | — | US | claimed |
| EP-4110270-B1 | ORAL CARE COMPOSITIONS FOR GUM HEALTH | PROCTER & GAMBLE (US) | 2025-04-09 | — | — | EP | claimed |
| EP-4069099-B1 | APPARATUS FOR DELIVERY OF A TISSUE REGENERATIVE MULTI-DRUG COCKTAIL | TUFTS COLLEGE (US) | 2025-04-09 | — | — | EP | claimed |
| EP-3946643-B1 | USE OF POLYLYSINE DENDRIMERS IN THE PREVENTION AND MANAGEMENT OF ACNE-PRONE SKIN AND ACNEIC SKIN | LUCAS MEYER COSMETICS (FR) | 2025-04-02 | — | — | EP | claimed |
| EP-3634380-B1 | INHIBITION OF CRYSTAL GROWTH OF ROFLUMILAST | ARCUTIS BIOTHERAPEUTICS INC (US) | 2024-01-10 | — | — | EP | claimed |
| EP-4057999-B1 | PROCESS FOR PREPARING NANO- OR MICROPARTICLES COMPRISING A CARRIER-POLYMER AND ONE OR MORE BIOLOGICALLY ACTIVE INGREDIENTS | EVONIK OPERATIONS GMBH (DE) | 2023-12-13 | — | — | EP | claimed |
| EP-3684334-B1 | PHARMACEUTICAL COMPOSITIONS OF ROFLUMILAST IN AQUEOUS BLENDS OF WATER-MISCIBLE, PHARMACEUTICALLY ACCEPTABLE SOLVENTS | ARCUTIS BIOTHERAPEUTICS INC (US) | 2023-12-06 | — | — | EP | claimed |
| US-11819576-B2 | Process for preparing nano-or microparticles comprising a carrier-polymer and one or more biologically active ingredients | EVONIK OPERATIONS GMBH (DE) | 2023-11-21 | — | — | US | claimed |
| EP-3311802-B1 | TOPICAL PHARMACEUTICAL COMPOSITION BASED ON SEMIFLUORINATED ALKANES | DERMALIQ THERAPEUTICS INC (US) | 2023-11-01 | — | — | EP | claimed |
| EP-3532110-B1 | FORMULATIONS FOR OXYGEN DELIVERY TO BODY TISSUES | OXY SOLUTIONS AS (NO) | 2023-06-07 | — | — | EP | claimed |
| US-20230147853-A1 | PROCESS FOR PREPARING NANO- OR MICROPARTICLES COMPRISING A CARRIER-POLYMER AND ONE OR MORE BIOLOGICALLY ACTIVE INGREDIENTS | EVONIK OPERATIONS GMBH (DE) | 2023-05-11 | — | — | US | claimed |
| CN-115209861-A | Oral care compositions for gum health | 宝洁公司 | 2022-10-18 | — | — | CN | claimed |
| EP-4057999-A1 | PROCESS FOR PREPARING NANO- OR MICROPARTICLES COMPRISING A CARRIER-POLYMER AND ONE OR MORE BIOLOGICALLY ACTIVE INGREDIENTS | Evonik Operations GmbH (DE) | 2022-09-21 | — | — | EP | claimed |
| EP-1931320-B1 | MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL DOSAGE FORM COMPRISING THE SAME | FLAMEL IRELAND LTD (IE) | 2022-06-15 | — | — | EP | claimed |
| EP-2109445-B1 | COMPOSITIONS FOR TOPICAL APPLICATION COMPRISING A PEROXIDE AND RETINOID | SOL GEL TECH LTD (IL) | 2022-04-20 | — | — | EP | claimed |
| WO-2026104588-A1 | UROLITHIN COMBINATION | AMAZENTIS SA (CH) | 2026-05-21 | — | — | WO | disclosed |
| US-11254690-B2 | PTEFb inhibiting macrocyclic compounds | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-02-22 | — | — | US | disclosed |
| US-11242356-B2 | PTEFb inhibiting macrocyclic compounds | BAYER AKTIENGESELLSCHAFT (DE) | 2022-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11242356-B2 | PTEFb inhibiting macrocyclic compounds | PCLAF, PPIB, RHEB | RARA 3676/4885RARB 1381/4885RARG 3500/4885 |
| US-11254690-B2 | PTEFb inhibiting macrocyclic compounds | PCLAF, PPIB, RHEB | RARA 3676/4885RARB 1381/4885RARG 3500/4885 |
| US-20260125650-A1 | METHODS AND COMPOSITIONS FOR GENERATING HEPATOCYTES | WNT3A, GSK3B, GSK3A | RARA 354/4885RARB 70/4885RARG 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.